{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:22:51Z","timestamp":1787628171350,"version":"build-2736575974"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2019,10,2]]},"abstract":"<jats:sec><jats:title\/><jats:p>There is increasing evidence that menopause is associated with the progression and severity of non-alcoholic fatty liver disease (NAFLD). Estrogen deficiency worsens non-alcoholic steatohepatitis (NASH) in mice models with fatty liver. The prevalence of NAFLD seems to be higher in postmenopausal compared with premenopausal women. Although more data are needed, lower serum estradiol levels are associated with NASH in postmenopausal women. Apart from estrogen deficiency, relative androgen excess and decrease in sex hormone-binding protein are observed in postmenopausal women. These hormonal changes seem to interplay with an increase in abdominal adipose mass, also observed in postmenopausal women, and aging, which are both closely related to the severity and progressive forms of NAFLD. NAFLD adds extra morbidity to postmenopausal women, possibly increasing the risk of type 2 diabetes mellitus and cardiovascular disease. Improving parameters of the metabolic syndrome via modifications in diet and physical exercise may reduce the risk of NAFLD and its related morbidity. Limited studies have shown a beneficial effect of hormone replacement therapy (HRT) on NAFLD, although adverse hepatic effects have been attributed to progesterone in one study. Phytoestrogens may be alternatives to HRT, but their long-term efficacy and safety remain to be shown. The aim of this review was to summarize evidence linking menopause with NAFLD with a special focus on potential therapeutic perspectives.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570161116666180711121949","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T11:51:16Z","timestamp":1531309876000},"page":"546-555","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives"],"prefix":"10.2174","volume":"17","author":[{"given":"Vasiliki","family":"Venetsanaki","sequence":"first","affiliation":[{"name":"Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"First Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Fazel Y.","year":"2016","unstructured":"Fazel Y.; Koenig A.B.; Sayiner M.; Goodman Z.D.; Younossi Z.M.; Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016,65(8),1017-1025","journal-title":"Metabolism"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.metabol.2016.02.013","volume":"65","author":"Khan R.S.","year":"2016","unstructured":"Khan R.S.; Newsome P.N.; Non-alcoholic fatty liver disease and liver transplantation. Metabolism 2016,65(8),1208-1223","journal-title":"Metabolism"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"9","author":"Polyzos S.","year":"2009","unstructured":"Polyzos S.; Kountouras J.; Zavos C.; Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009,9(3),299-314","journal-title":"Curr Mol Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"Rinella M.E.","year":"2015","unstructured":"Rinella M.E.; Nonalcoholic fatty liver disease. JAMA 2015,313(22),2263","journal-title":"JAMA"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"Katsiki N.","year":"2016","unstructured":"Katsiki N.; Mikhailidis D.P.; Mantzoros C.S.; Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016,65(8),1109-1123","journal-title":"Metabolism"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016,59(6),1121-1140","journal-title":"Diabetologia"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","volume":"46","author":"Polyzos S.A.","year":"2012","unstructured":"Polyzos S.A.; Kountouras J.; Zavos C.; Deretzi G.; Nonalcoholic fatty liver disease. J Clin Gastroenterol 2012,46(4),272-284","journal-title":"J Clin Gastroenterol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","volume":"9","author":"Gutierrez-Grobe Y.","year":"2010","unstructured":"Gutierrez-Grobe Y.; Ponciano-Rodr\u00edguez G.; Ramos M.H.; Uribe M.; M\u00e9ndez-S\u00e1nchez N.; Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010,9(4),402-409","journal-title":"Ann Hepatol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF03401306","volume":"12","author":"Polyzos S.A.","year":"2013","unstructured":"Polyzos S.A.; Kountouras J.; Tsatsoulis A.; Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones (Athens) 2013,12(3),405-416","journal-title":"Hormones (Athens)"},{"key":"ref=10","first-page":"1031","volume":"301","author":"Kamada Y.","year":"2011","unstructured":"Kamada Y.; Kiso S.; Yoshida Y.; Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Liver Physiol 2011,301(6),1031-1043","journal-title":"Am J Physiol Liver Physiol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2265.2006.02543.x","volume":"65","author":"McKenzie J.","year":"2006","unstructured":"McKenzie J.; Fisher B.M.; Jaap A.J.; Stanley A.; Paterson K.; Sattar N.; Effects of HRT on liver enzyme levels in women with type 2 diabetes: A randomized placebo-controlled trial. Clin Endocrinol (Oxf) 2006,65(1),40-44","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=12","first-page":"127","volume":"13","author":"Polyzos S.A.","year":"2009","unstructured":"Polyzos S.A.; Kountouras J.; Zavos C.; The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia 2009,13(2),127","journal-title":"Hippokratia"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gut.2004.053728","volume":"54","author":"Itagaki T.","year":"2005","unstructured":"Itagaki T.; Shimizu I.; Cheng X.; Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 2005,54(12),1782-1789","journal-title":"Gut"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/gut.44.1.127","volume":"44","author":"Shimizu I.","year":"1999","unstructured":"Shimizu I.; Mizobuchi Y.; Yasuda M.; Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999,44(1),127-136","journal-title":"Gut"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.510290307","volume":"29","author":"Yasuda M.","year":"1999","unstructured":"Yasuda M.; Shimizu I.; Shiba M.; Ito S.; Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999,29(3),719-727","journal-title":"Hepatology"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0022-4731(83)90400-4","volume":"19","author":"Lax E.R.","year":"1983","unstructured":"Lax E.R.; Tamulevicius P.; M\u00fcller A.; Schriefers H.; Hepatic nuclear estrogen receptor concentrations in the rat-influence of age, sex, gestation, lactation and estrous cycle. J Steroid Biochem 1983,19(2),1083-1088","journal-title":"J Steroid Biochem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/294278","volume":"2015","author":"Shen M.","year":"2015","unstructured":"Shen M.; Shi H.; Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol 2015,2015,1-12","journal-title":"Int J Endocrinol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.1073\/pnas.95.12.6965","volume":"95","author":"Fisher C.R.","year":"1998","unstructured":"Fisher C.R.; Graves K.H.; Parlow A.F.; Simpson E.R.; Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998,95(12),6965-6970","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1073\/pnas.97.23.12735","volume":"97","author":"Jones M.E.","year":"2000","unstructured":"Jones M.E.; Thorburn A.W.; Britt K.L.; Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA 2000,97(23),12735-12740","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"12729","DOI":"10.1073\/pnas.97.23.12729","volume":"97","author":"Heine P.A.","year":"2000","unstructured":"Heine P.A.; Taylor J.A.; Iwamoto G.A.; Lubahn D.B.; Cooke P.S.; Increased adipose tissue in male and female estrogen receptor-\u03b1 knockout mice. Proc Natl Acad Sci USA 2000,97(23),12729-12734","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/gme.0b013e31817b8159","volume":"15","author":"Paquette A.","year":"2008","unstructured":"Paquette A.; Wang D.; Jankowski M.; Gutkowska J.; Lavoie J-M.; Effects of ovariectomy on PPAR\u03b1, SREBP-1c, and SCD-1 gene expression in the rat liver. Menopause 2008,15(6),1169-1175","journal-title":"Menopause"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.maturitas.2007.08.002","volume":"58","author":"Paquette A.","year":"2007","unstructured":"Paquette A.; Shinoda M.; Lhoret R.R.; Prud\u2019homme D.; Lavoie J-M.; Time course of liver lipid infiltration in ovariectomized rats: Impact of a high-fat diet. Maturitas 2007,58(2),182-190","journal-title":"Maturitas"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.physbeh.2008.05.024","volume":"95","author":"Barsalani R.","year":"2008","unstructured":"Barsalani R.; Pighon A.; Rabasa-Lhoret R.; Yasari S.; Lavoie J-M.; Liver of ovariectomized rats is resistant to resorption of lipids. Physiol Behav 2008,95(1-2),216-221","journal-title":"Physiol Behav"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.maturitas.2008.02.005","volume":"59","author":"Corriveau P.","year":"2008","unstructured":"Corriveau P.; Paquette A.; Brochu M.; Prud\u2019homme D.; Rabasa-Lhoret R.; Lavoie J-M.; Resistance training prevents liver fat accumulation in ovariectomized rats. Maturitas 2008,59(3),259-267","journal-title":"Maturitas"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00421-011-2098-6","volume":"112","author":"Domingos M.M.","year":"2012","unstructured":"Domingos M.M.; Rodrigues M.F.C.; Stotzer U.S.; Resistance training restores the gene expression of molecules related to fat oxidation and lipogenesis in the liver of ovariectomized rats. Eur J Appl Physiol 2012,112(4),1437-1444","journal-title":"Eur J Appl Physiol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.metabol.2010.06.012","volume":"60","author":"Pighon A.","year":"2011","unstructured":"Pighon A.; Gutkowska J.; Jankowski M.; Rabasa-Lhoret R.; Lavoie J-M.; Exercise training in ovariectomized rats stimulates estrogenic-like effects on expression of genes involved in lipid accumulation and subclinical inflammation in liver. Metabolism 2011,60(5),629-639","journal-title":"Metabolism"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1172\/JCI9575","volume":"105","author":"Nemoto Y.","year":"2000","unstructured":"Nemoto Y.; Toda K.; Ono M.; Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000,105(12),1819-1825","journal-title":"J Clin Invest"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"35983","DOI":"10.1074\/jbc.M507339200","volume":"280","author":"D\u2019Eon T.M.","year":"2005","unstructured":"D\u2019Eon T.M.; Souza S.C.; Aronovitz M.; Obin M.S.; Fried S.K.; Greenberg A.S.; Estrogen regulation of adiposity and fuel partitioning. J Biol Chem 2005,280(43),35983-35991","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3892\/mmr.2016.5236","volume":"14","author":"Fu X.","year":"2016","unstructured":"Fu X.; Xing L.; Xu W.; Shu J.; Treatment with estrogen protects against ovariectomy-induced hepatic steatosis by increasing AQP7 expression. Mol Med Rep 2016,14(1),425-431","journal-title":"Mol Med Rep"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/db11-1718","volume":"62","author":"Zhu L.","year":"2013","unstructured":"Zhu L.; Brown W.C.; Cai Q.; Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013,62(2),424-434","journal-title":"Diabetes"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1007\/s10620-015-3660-6","volume":"60","author":"Luo F.","year":"2015","unstructured":"Luo F.; Ishigami M.; Achiwa K.; Raloxifene ameliorates liver fibrosis of nonalcoholic steatohepatitis induced by choline-deficient high-fat diet in ovariectomized mice. Dig Dis Sci 2015,60(9),2730-2739","journal-title":"Dig Dis Sci"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jnutbio.2016.08.007","volume":"38","author":"Panneerselvam S.","year":"2016","unstructured":"Panneerselvam S.; Packirisamy R.M.; Bobby Z.; Elizabeth J.S.; Sridhar M.G.; Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). J Nutr Biochem 2016,38,57-69","journal-title":"J Nutr Biochem"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.nut.2008.11.027","volume":"25","author":"Choi J.S.","year":"2009","unstructured":"Choi J.S.; Song J.; Effect of genistein on insulin resistance, renal lipid metabolism, and antioxidative activities in ovariectomized rats. Nutrition 2009,25(6),676-685","journal-title":"Nutrition"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ijo.2010.256","volume":"35","author":"Kim M.H.","year":"2011","unstructured":"Kim M.H.; Park J.S.; Jung J.W.; Byun K.W.; Kang K.S.; Lee Y.S.; Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes 2011,35(8),1019-1030","journal-title":"Int J Obes"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.33573","volume":"122","author":"Clark J.M.","year":"2002","unstructured":"Clark J.M.; Brancati F.L.; Diehl A.M.; Nonalcoholic fatty liver disease. Gastroenterology 2002,122(6),1649-1657","journal-title":"Gastroenterology"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00535-003-1178-8","volume":"38","author":"Kojima S.","year":"2003","unstructured":"Kojima S.; Watanabe N.; Numata M.; Ogawa T.; Matsuzaki S.; Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol 2003,38(10),954-961","journal-title":"J Gastroenterol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2005.04086.x","volume":"21","author":"Park Sh.","year":"2006","unstructured":"Park Sh.; Jeon Wk.; Kim Sh.; Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006,21(1),138-143","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/gut.2006.115345","volume":"56","author":"V\u00f6lzke H.","year":"2007","unstructured":"V\u00f6lzke H.; Schwarz S.; Baumeister S.E.; Menopausal status and hepatic steatosis in a general female population. Gut 2007,56(4),594-595","journal-title":"Gut"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/13697137.2014.881353","volume":"17","author":"Bruno A de S.","year":"2014","unstructured":"Bruno A de S.; Rodrigues M.H.; Alvares M.C.B.; Nahas-Neto J.; Nahas E.A.P.; Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. Climacteric 2014,17(4),465-471","journal-title":"Climacteric"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/GME.0000000000000352","volume":"22","author":"Wang Z.","year":"2015","unstructured":"Wang Z.; Xu M.; Hu Z.; Shrestha U.K.; Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index. Menopause 2015,22(6),667-673","journal-title":"Menopause"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","volume":"51","author":"S\u00f6derberg C.","year":"2010","unstructured":"S\u00f6derberg C.; St\u00e5l P.; Askling J.; Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010,51(2),595-602","journal-title":"Hepatology"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.26761","volume":"59","author":"Yang J.D.","year":"2014","unstructured":"Yang J.D.; Abdelmalek M.F.; Pang H.; Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014,59(4),1406-1414","journal-title":"Hepatology"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.27097","volume":"60","author":"Yoneda M.","year":"2014","unstructured":"Yoneda M.; Thomas E.; Sumida Y.; Eguchi Y.; Schiff E.R.; The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology 2014,60(5),1792","journal-title":"Hepatology"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","volume":"65","author":"Polyzos S.A.","year":"2016","unstructured":"Polyzos S.A.; Mantzoros C.S.; Nonalcoholic fatty future disease. Metabolism 2016,65(8),1007-1016","journal-title":"Metabolism"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1753-0407.12379","volume":"9","author":"Lu J.","year":"2017","unstructured":"Lu J.; Zhang J.; Du R.; Age at menarche is associated with the prevalence of non-alcoholic fatty liver disease later in life. J Diabetes 2017,9(1),53-60","journal-title":"J Diabetes"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/oby.20950","volume":"23","author":"Mueller N.T.","year":"2015","unstructured":"Mueller N.T.; Pereira M.A.; Demerath E.W.; Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult BMI: The CARDIA study. Obesity (Silver Spring) 2015,23(2),468-474","journal-title":"Obesity (Silver Spring)"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.28514","volume":"64","author":"Klair J.S.","year":"2016","unstructured":"Klair J.S.; Yang J.D.; Abdelmalek M.F.; A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016,64(1),85-91","journal-title":"Hepatology"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/GME.0000000000000500","volume":"23","author":"Matsuo K.","year":"2016","unstructured":"Matsuo K.; Gualtieri M.R.; Cahoon S.S.; Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer. Menopause 2016,23(2),189-196","journal-title":"Menopause"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(05)78493-2","volume":"351","author":"Ogawa Y.","year":"1998","unstructured":"Ogawa Y.; Murata Y.; Nishioka A.; Inomata T.; Yoshida S.; Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998,351(9104),725","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","volume":"330","author":"Bruno S.","year":"2005","unstructured":"Bruno S.; Maisonneuve P.; Castellana P.; Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005,330(7497),932","journal-title":"BMJ"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2169\/internalmedicine.41.345","volume":"41","author":"Nemoto Y.","year":"2002","unstructured":"Nemoto Y.; Saibara T.; Ogawa Y.; Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 2002,41(5),345-350","journal-title":"Intern Med"},{"key":"ref=52","first-page":"1473","volume":"10","author":"Ogawa Y.","year":"2003","unstructured":"Ogawa Y.; Murata Y.; Saibara T.; Nishioka A.; Kariya S.; Yoshida S.; Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol Rep 2003,10(5),1473-1478","journal-title":"Oncol Rep"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00042737-200406000-00013","volume":"16","author":"Elefsiniotis I.S.","year":"2004","unstructured":"Elefsiniotis I.S.; Pantazis K.D.; Ilias A.; Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: The role of glucose intolerance. Eur J Gastroenterol Hepatol 2004,16(6),593-598","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1023\/A:1008354429921","volume":"11","author":"Moffat D.F.","year":"2000","unstructured":"Moffat D.F.; Oien K.A.; Dickson J.; Habeshaw T.; McLellan D.R.; Hepatocellular carcinoma after long-term tamoxifen therapy. Ann Oncol 2000,11(9),1195-1196","journal-title":"Ann Oncol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7326\/0003-4819-123-3-199508010-00018","volume":"123","author":"Pratt D.S.","year":"1995","unstructured":"Pratt D.S.; Knox T.A.; Erban J.; Tamoxifen-induced steatohepatitis. Ann Intern Med 1995,123(3),236","journal-title":"Ann Intern Med"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(05)74872-8","volume":"353","author":"Oien K.A.","year":"1999","unstructured":"Oien K.A.; Moffat D.; Curry G.W.; Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999,353(9146),36-37","journal-title":"Lancet"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv-11-1-80","volume":"11","author":"Rosner W.","year":"1990","unstructured":"Rosner W.; The functions of corticosteroid-binding globulin and sex hormone-binding globulin: Recent Advances. Endocr Rev 1990,11(1),80-91","journal-title":"Endocr Rev"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0026-0495(97)90159-1","volume":"46","author":"Pasquali R.","year":"1997","unstructured":"Pasquali R.; Vicennati V.; Bertazzo D.; Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Metabolism 1997,46(1),5-9","journal-title":"Metabolism"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"14532","DOI":"10.1038\/s41598-017-15232-9","volume":"7","author":"Hua X.","year":"2017","unstructured":"Hua X.; Li M.; Pan F.; Xiao Y.; Cui W.; Hu Y.; Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients. Sci Rep 2017,7(1),14532","journal-title":"Sci Rep"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0043-102690","volume":"49","author":"Ye J.","year":"2017","unstructured":"Ye J.; Yao Z.; Tan A.; Low serum sex hormone-binding globulin associated with insulin resistance in men with nonalcoholic fatty liver disease. Horm Metab Res 2017,49(5),359-364","journal-title":"Horm Metab Res"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5604\/01.3001.0009.8593","volume":"16","author":"Jaruvongvanich V.","year":"2017","unstructured":"Jaruvongvanich V.; Sanguankeo A.; Riangwiwat T.; Upala S.; Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Ann Hepatol 2017,16(3),382-394","journal-title":"Ann Hepatol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.cgh.2014.12.033","volume":"13","author":"Lazo M.","year":"2015","unstructured":"Lazo M.; Zeb I.; Nasir K.; Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol 2015,13(9),1686-1693","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5114\/aoms.2017.68972","volume":"5","author":"Klisic A.","year":"2017","unstructured":"Klisic A.; Kavaric N.; Jovanovic M.; Soldatovic I.; Gligorovic-Barhanovic N.; Kotur-Stevuljevic J.; Bioavailable testosterone is independently associated with fatty liver index in postmenopausal women. Arch Med Sci 2017,5(5),1188-1196","journal-title":"Arch Med Sci"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ajg.2017.44","volume":"112","author":"Sarkar M.","year":"2017","unstructured":"Sarkar M.; Wellons M.; Cedars M.I.; Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife. Am J Gastroenterol 2017,112(5),755-762","journal-title":"Am J Gastroenterol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.3748\/wjg.v20.i26.8351","volume":"20","author":"Vassilatou E.","year":"2014","unstructured":"Vassilatou E.; Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014,20(26),8351-8363","journal-title":"World J Gastroenterol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"519","DOI":"10.14310\/horm.2002.1493","volume":"13","author":"Polyzos S.","year":"2014","unstructured":"Polyzos S.; Goulis D.; Kountouras J.; Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones 2014,13(4),519-531","journal-title":"Hormones"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/17455057.5.2.191","volume":"5","author":"Suzuki A.","year":"2009","unstructured":"Suzuki A.; Abdelmalek M.F.; nonalcoholic fatty liver disease in women. Women Health 2009,5(2),191-203","journal-title":"Women Health"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s40618-017-0708-9","volume":"40","author":"Rocha A.L.L.","year":"2017","unstructured":"Rocha A.L.L.; Faria L.C.; Guimar\u00e3es T.C.M.; Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Endocrinol Invest 2017,40(12),1279-1288","journal-title":"J Endocrinol Invest"},{"key":"ref=69","first-page":"17","volume":"40","author":"Mccullough A.J.","year":"2006","unstructured":"Mccullough A.J.; Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006,40,17-29","journal-title":"J Clin Gastroenterol"},{"key":"ref=70","first-page":"92","volume":"42","author":"Polyzos S.A.","year":"2017","unstructured":"Polyzos S.A.; Kountouras J.; Mantzoros C.S.; Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 2017,42(2),92-108","journal-title":"Minerva Endocrinol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archinte.163.4.427","volume":"163","author":"Park Y-W.","year":"2003","unstructured":"Park Y-W.; Zhu S.; Palaniappan L.; Heshka S.; Carnethon M.R.; Heymsfield S.B.; The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med 2003,163(4),427-436","journal-title":"Arch Intern Med"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2003-030242","volume":"88","author":"Carr M.C.","year":"2003","unstructured":"Carr M.C.; The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003,88(6),2404-2411","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/107155769400100210","volume":"1","author":"Lindheim S.R.","year":"1994","unstructured":"Lindheim S.R.; Buchanan T.A.; Duffy D.M.; Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1994,1(2),150-154","journal-title":"J Soc Gynecol Investig"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2362.1993.tb00792.x","volume":"23","author":"Walton C.","year":"1993","unstructured":"Walton C.; Godsland I.F.; Proudler A.J.; Wynn V.; Stevenson J.C.; The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993,23(8),466-473","journal-title":"Eur J Clin Invest"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12072-012-9412-1","volume":"7","author":"Kim S.","year":"2013","unstructured":"Kim S.; Choi J.; Kim M.; Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components. Hepatol Int 2013,7(2),586-591","journal-title":"Hepatol Int"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3889\/oamjms.2016.024","volume":"4","author":"Bitoska I.","year":"2016","unstructured":"Bitoska I.; Krstevska B.; Milenkovic T.; Effects of hormone replacement therapy on insulin resistance in postmenopausal diabetic women. Open Access Maced J Med Sci 2016,4(1),83-88","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s001250050758","volume":"40","author":"Brussaard H.E.","year":"1997","unstructured":"Brussaard H.E.; Gevers Leuven J.A.; Fr\u00f6lich M.; Kluft C.; Krans H.M.; Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997,40(7),843-849","journal-title":"Diabetologia"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","volume":"17","author":"Mintziori G.","year":"2016","unstructured":"Mintziori G.; Polyzos S.A.; Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 2016,17(14),1937-1946","journal-title":"Expert Opin Pharmacother"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","volume":"16","author":"Said A.","year":"2017","unstructured":"Said A.; Akhter A.; Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 2017,16(4),538-547","journal-title":"Ann Hepatol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","volume":"65","author":"Polyzos S.A.","year":"2016","unstructured":"Polyzos S.A.; Mantzoros C.S.; Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism 2016,65(9),1297-1306","journal-title":"Metabolism"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","volume":"68","author":"Katsagoni C.N.","year":"2017","unstructured":"Katsagoni C.N.; Georgoulis M.; Papatheodoridis G.V.; Panagiotakos D.B.; Kontogianni M.D.; Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism 2017,68,119-132","journal-title":"Metabolism"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2016.04.036","volume":"14","author":"Orci L.A.","year":"2016","unstructured":"Orci L.A.; Gariani K.; Oldani G.; Delaune V.; Morel P.; Toso C.; Exercise-based interventions for nonalcoholic fatty liver disease: A meta-analysis and meta-regression. Clin Gastroenterol Hepatol 2016,14(10),1398-1411","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ijo.2016.4","volume":"40","author":"Otten J.","year":"2016","unstructured":"Otten J.; Mellberg C.; Ryberg M.; Strong and persistent effect on liver fat with a paleolithic diet during a two-year intervention. Int J Obes 2016,40(5),747-753","journal-title":"Int J Obes"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","volume":"56","author":"Parker H.M.","year":"2012","unstructured":"Parker H.M.; Johnson N.A.; Burdon C.A.; Cohn J.S.; O\u2019Connor H.T.; George J.; Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012,56(4),944-951","journal-title":"J Hepatol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/GME.0000000000000647","volume":"23","author":"Rezende R.E.F.","year":"2016","unstructured":"Rezende R.E.F.; Duarte S.M.B.; Stefano J.T.; Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. Menopause 2016,23(8),876-883","journal-title":"Menopause"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"15952","DOI":"10.1038\/s41598-017-16159-x","volume":"7","author":"Cheng S.","year":"2017","unstructured":"Cheng S.; Ge J.; Zhao C.; Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep 2017,7(1),15952","journal-title":"Sci Rep"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"Manson J.E.","year":"2013","unstructured":"Manson J.E.; Chlebowski R.T.; Stefanick M.L.; Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women\u2019s health initiative randomized trials. JAMA 2013,310(13),1353","journal-title":"JAMA"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-28032013000200032","volume":"50","year":"2013","unstructured":"Florentino Gs de A, Cotrim Hp, Vilar Cp, Florentino Av de A, Guimaraes Gma, Barreto Vst. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol 2013,50(3),180-185","journal-title":"Arq Gastroenterol"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cgh.2016.07.034","volume":"15","author":"Yang J.D.","year":"2017","unstructured":"Yang J.D.; Abdelmalek M.F.; Guy C.D.; Patient sex, reproductive status, and synthetic hormone use associate with Histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2017,15(1),127-131","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/13697137.2012.662251","volume":"16","author":"Barsalani R.","year":"2013","unstructured":"Barsalani R.; Riesco E.; Lavoie J-M.; Dionne I.J.; Effect of exercise training and isoflavones on hepatic steatosis in overweight postmenopausal women. Climacteric 2013,16(1),88-95","journal-title":"Climacteric"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"Adams L.A.","year":"2017","unstructured":"Adams L.A.; Anstee Q.M.; Tilg H.; Targher G.; Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017,66(6),1138-1153","journal-title":"Gut"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00774-016-0807-2","volume":"35","author":"Upala S.","year":"2017","unstructured":"Upala S.; Jaruvongvanich V.; Wijarnpreecha K.; Sanguankeo A.; Nonalcoholic fatty liver disease and osteoporosis: A systematic review and meta-analysis. J Bone Miner Metab 2017,35(6),685-693","journal-title":"J Bone Miner Metab"},{"key":"ref=93","volume":"12","author":"Eslami L.","year":"2013","unstructured":"Eslami L.; Merat S.; Malekzadeh R.; Nasseri-Moghaddam S.; Aramin H.; Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013,12","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","volume":"21","author":"Kargiotis K.","year":"2015","unstructured":"Kargiotis K.; Athyros V.G.; Giouleme O.; Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015,21(25),7860","journal-title":"World J Gastroenterol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","volume":"71","author":"Athyros V.G.","year":"2017","unstructured":"Athyros V.G.; Alexandrides T.K.; Bilianou H.; The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017,71,17-32","journal-title":"Metabolism"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1196\/annals.1386.044","volume":"1089","author":"Giannitrapani L.","year":"2006","unstructured":"Giannitrapani L.; Soresi M.; LaSpada E.; Cervello M.; D\u2019Alessandro N.; Montalto G.; Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006,1089(1),228-236","journal-title":"Ann N Y Acad Sci"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"941","DOI":"10.5604\/16652681.1171803","volume":"14","author":"Polyzos S.A.","year":"2015","unstructured":"Polyzos S.A.; Goulis D.G.; Kountouras J.; Nonalcoholic fatty liver disease and polycystic ovary syndrome. Ann Hepatol 2015,14(6),941-943","journal-title":"Ann Hepatol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3748\/wjg.14.3396","volume":"14","author":"Sporea I.","year":"2008","unstructured":"Sporea I.; Popescu A.; Sirli R.; Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol 2008,14(21),3396","journal-title":"World J Gastroenterol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","volume":"63","author":"Polyzos S.A.","year":"2014","unstructured":"Polyzos S.A.; Mantzoros C.S.; Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014,63(2),161-167","journal-title":"Metabolism"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"Vilar-Gomez E.","year":"2018","unstructured":"Vilar-Gomez E.; Chalasani N.; Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018,68(2),305-315","journal-title":"J Hepatol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/163682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T18:10:01Z","timestamp":1751739001000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/163682\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,10,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161116666180711121949","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}